Vasculitis & polymyalgia rheumatica
CCL23 is a potential biomarker for antineutrophil cytoplasmic antibody–associated vasculitis
Authors' conclusion
Elevated serum CCL23 level was closely related with disease activity and renal involvement in patients with AAV, can be a potential biomarker for diagnosis, and can predict prognosis in patients with AAV, especially adverse renal prognosis.
Study context
- Population
- Patients with antibody-associated vasculitis (AAV) and healthy controls
- Participants
- 317 vs 83
- Exposure
- Patients with AAV vs healthy controls
- AAVn = 317
- Healthy controls (HCs)n = 83reference
- Outcome
- Value of serum CCL23 in diagnosis, disease activity and prognosis of AAV
Main finding
As reported in the abstract
Serum CCL23 level and its diagnostic, activity and prognostic value
- Distinguishing relapse from remission, AUC: CCL23
- 0.942
- Distinguishing relapse from remission, AUC: Birmingham vasculitis activity score (BVAS)
- 0.84
- Elevated CCL23 associated with poor prognosis within 1 year follow-up
- p = 0.0001
Observational data: associations, not effects.
Further findings
Renal involvement · at diagnosis
- Elevated CCL23 as risk factor for renal involvement, OR
- 1.722, p = 0.033
- Correlation with serum creatinine
- r = 0.381, p = 0.009
- Correlation with eGFR
- r = - 0.382, p = 0.01
Adverse outcomes in AAV with renal involvement, high CCL23 at diagnosis (subgroup) · 1 year follow-up
- High CCL23 associated with increased adverse outcomes
- P = 0.0242
Original publication
CCL23 is a potential biomarker for antineutrophil cytoplasmic antibody–associated vasculitis. Arthritis Res Ther. Published 10 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →